Chemokine Receptor Antagonists: From the Bench to the Clinic

Leukocyte Trafficking: Molecular Mechanisms, Therapeutic Targets, and Methods

Volumn , Issue , 2006, Pages 371-402

  Ribeiro, Sofia ^a   Horuk, Richard ^a  

^a BAYER AG   (Germany)

Author keywords

Chemokine receptor; Chemokine receptor antagonists; Chemokines; CXC chemokine receptor antagonists; Leukocyte trafficking; Therapeutic targets; Trafficking mechanisms

Indexed keywords

EID: 84889449003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/352760779X.ch16     Document Type: Chapter

References (105)

1. Atnip, K.D., L.M. Carter, G.L. Nicolson, and M.K. Dabbous. 1987. Chemotactic response of rat mammary adenocarcinoma cell clones to tumor-derived cytokines. Biochem Biophys Res Commun 146:996-1002.
2. Sevenet, T. 1991. Looking for new drugs: what criteria? J Ethnopharmacol 32:83-90.
3. Gerard, C., and N.P. Gerard. 2001. Chemokines: back to the future? Nat Cell Biol 3:E53-54.
4. Horuk, R. 2003. Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29:369-375.
5. Delgado, M.B., I. Clark-Lewis, P. Loetscher, H. Langen, M. Thelen, M. Baggiolini, and M. Wolf. 2001. Rapid inactivation of stromal cellderived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol 31:699-707.
6. Liang, M., C. Mallari, M. Rosser, H.P. Ng, K. May, S. Monahan, J.G. Bauman, I. Islam, A. Ghannam, B. Buckman, K. Shaw, G.P. Wei, W. Xu, Z. Zhao, E. Ho, J. Shen, H. Oanh, B. Subramanyam, R. Vergona, D. Taub, L. Dunning, S. Harvey, R.M. Snider, J. Hesselgesser, M.M. Morrissey, and H.D. Perez. 2000. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 275:19000-19008.
7. Horuk, R., C. Clayberger, A.M. Krensky, Z. Wang, H.J. Grone, C. Weber, K.S. Weber, P.J. Nelson, K. May, M. Rosser, L. Dunning, M. Liang, B. Buckman, A. Ghannam, H.P. Ng, I. Islam, J.G. Bauman, G.P. Wei, S. Monahan, W. Xu, R.M. Snider, M.M. Morrissey, J. Hesselgesser, and H.D. Perez. 2001. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 276:4199-4204.
8. Anders, H.J., V. Vielhauer, M. Frink, Y. Linde, C.D. Cohen, S.M. Blattner, M. Kretzler, F. Strutz, M. Mack, H.J. Grone, J. Onuffer, R. Horuk, P.J. Nelson, and D. Schlondorff. 2002. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 109:251-259.
9. Gao, J.L., T.A. Wynn, Y. Chang, E.J. Lee, H.E. Broxmeyer, S. Cooper, H.L. Tiffany, H. Westphal, J. Kwon-Chung, and P.M. Murphy. 1997. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med 185:1959-1968.
10. Rottman, J.B., A.J. Slavin, R. Silva, H.L. Weiner, C.G. Gerard, and W.W. Hancock. 2000. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 30:2372-2377.
11. Horuk, R., S. Shurey, H.P. Ng, K. May, J.G. Bauman, I. Islam, A. Ghannam, B. Buckman, G.P. Wei, W. Xu, M. Liang, M. Rosser, L. Dunning, J. Hesselgesser, R.M. Snider, M.M. Morrissey, H.D. Perez, and C. Green. 2001. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett 76:193-201.
12. Hesselgesser, J., H.P. Ng, M. Liang, W. Zheng, K. May, J.G. Bauman, S. Monahan, I. Islam, G.P. Wei, A. Ghannam, D.D. Taub, M. Rosser, R.M. Snider, M.M. Morrissey, H.D. Perez, and R. Horuk. 1998. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 273:15687-15692.
13. Anders, H.J., E. Belemezova, V. Eis, S. Segerer, V. Vielhauer, G. Perez de Lema, M. Kretzler, C.D. Cohen, M. Frink, R. Horuk, K.L. Hudkins, C.E. Alpers, F. Mampaso, and D. Schlondorff. 2004. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 15:1504-1513.
14. Eis, V., B. Luckow, V. Vielhauer, J.T. Siveke, Y. Linde, S. Segerer, G.P. De Lema, C.D. Cohen, M. Kretzler, M. Mack, R. Horuk, P.M. Murphy, J.L. Gao, K.L. Hudkins, C.E. Alpers, H.J. Grone, D. Schlondorff, and H.J. Anders. 2004. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 15:337-347.
15. Naya, A., M. Ishikawa, K. Matsuda, K. Ohwaki, T. Saeki, K. Noguchi, and N. Ohtake. 2003. Structureactivity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg Med Chem 11:875-884.
16. Saeki, T., and A. Naya. 2003. CCR1 chemokine receptor antagonist. Curr Pharm Des 9:1201-1208.
17. Gladue, R.P., S.H. Zwillich, A.T. Clucas, and M.F. Brown. 2004. CCR1 antagonists for the treatment of autoimmune diseases. Curr Opin Investig Drugs 5:499-504.
18. Kath, J.C., W.H. Brissette, M.F. Brown, M. Conklyn, A.P. DiRico, P. Dorff, R.P. Gladue, B.M. Lillie, P.D. Lira, E.N. Mairs, W.H. Martin, E.B. McElroy, M.A. McGlynn, T.J. Paradis, C.S. Poss, I.A. Stock, L.A. Tylaska, and D. Zheng. 2004. Potent small molecule CCR1 antagonists. Bioorg Med Chem Lett 14:2169-2173.
19. Kath, J.C., A.P. DiRico, R.P. Gladue, W.H. Martin, E.B. McElroy, I.A. Stock, L.A. Tylaska, and D. Zheng. 2004. The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. Bioorg Med Chem Lett 14:2163-2167.
20. Brown, M.F., M. Avery, W.H. Brissette, J.H. Chang, K. Colizza, M. Conklyn, A.P. DiRico, R.P. Gladue, J.C. Kath, S.S. Krueger, P.D. Lira, B.M. Lillie, G.D. Lundquist, E.N. Mairs, E.B. McElroy, M.A. McGlynn, T.J. Paradis, C.S. Poss, M.I. Rossulek, R.M. Shepard, J. Sims, T.J. Strelevitz, S. Truesdell, L.A. Tylaska, K. Yoon, and D. Zheng. 2004. Novel CCR1 antagonists with improved metabolic stability. Bioorg Med Chem Lett 14:2175-2179.
21. Millenium Pharmaceuticals. 2004. R and D at Millenium. http://www.mlnm.com/rd/inflammation/candidates/ccr1.asp
22. Horuk, R. 2000. CCR1. In Cytokine Database. S.K. Durum, Hirano, T., Vilcek, J. and Nicola, N.A., eds. Academic Press, San Diego. 2027-2041.
23. Carson, K.G., and G.C.B. Harriman. 2004. CCR1 antagonists and methods of use therefor. In US Patent Application 20040106639.
24. Harriman, G. 2004. Chemokine receptor antagonists: discovery of novel CCR1 antagonists as potential anti-inflammatories. Medicinal Chemistry Gordon Conference, Colby-Sawyer College, NH. August 2004.
25. Harriman, G.C.B., J. Shao, and J.R. Luly. 2000. Synthesis of 4-substituted 4-arylpiperidines. Tetrahedron Lett 41:8853-8856.
26. Haringman, J.J., M.C. Kraan, T.J. Smeets, K.H. Zwinderman, and P.P. Tak. 2003. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 62:715-721.
27. Fife, B.T., G.B. Huffnagle, W.A. Kuziel, and W.J. Karpus. 2000. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 192:899-905.
28. Izikson, L., R.S. Klein, I.F. Charo, H.L. Weiner, and A.D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192:1075-1080.
29. Boring, L., J. Gosling, M. Cleary, and I.F. Charo. 1998. Decreased lesion formation in CCR2-=- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897.
30. Dawson, T.C., W.A. Kuziel, T.A. Osahar, and N. Maeda. 1999. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143:205-211.
31. Imai, M., T. Shiota, K. Kataoka, C.M. Tarby, W.J. Moree, T. Tsutsumi, M. Sudo, M.M. Ramirez-Weinhouse, D. Comer, C.M. Sun, S. Yamagami, H. Tanaka, T. Morita, T. Hada, J. Greene, D. Barnum, J. Saunders, P.L. Myers, Y. Kato, and N. Endo. 2004. Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives. Bioorg Med Chem Lett 14:5407-5411.
32. Lapierre, J.M., D. Morgans, R. Wilhelm, and T.R. Mirzadagean. 1998. The synthesis and biological evaluation of potent MCP-1 inhibitors. 26th National Medicinal Chemistry Symposium, Richmond, VA. June 1998.
33. Forbes, I.T., D.G. Cooper, E.K. Dodds, D.M. Hickey, R.J. Ife, M. Meeson, M. Stockley, T.A. Berkhout, J. Gohil, P.H. Groot, and K. Moores. 2000. CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. Bioorg Med Chem Lett 10:1803-1806.
34. Mirzadegan, T., F. Diehl, B. Ebi, S. Bhakta, I. Polsky, D. McCarley, M. Mulkins, G.S. Weatherhead, J.M. Lapierre, J. Dankwardt, D. Morgans, Jr., R. Wilhelm, and K. Jarnagin. 2000. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 275:25562-25571.
35. Berkhout, T.A., F.E. Blaney, A.M. Bridges, D.G. Cooper, I.T. Forbes, A.D. Gribble, P.H. Groot, A. Hardy, R.J. Ife, R. Kaur, K.E. Moores, H. Shillito, J. Willetts, and J. Witherington. 2003. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 46:4070-4086.
36. Combadiere, C., S.K. Ahuja, and P.M. Murphy. 1995. Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene. DNA Cell Biol 14:673-680.
37. Heath, H., S.X. Qin, P. Rao, L.J. Wu, G. LaRosa, N. Kassam, P.D. Ponath, and C.R. Mackay. 1997. Chemokine receptor usage by human eosinophils-the importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 99:178-184.
38. Adachi, S., T. Nakano, H. Vliagoftis, and D.D. Metcalfe. 1999. Receptor-mediated modulation of murine mast cell function by alphamelanocyte stimulating hormone. J Immunol 163:3363-3368.
39. Garcia-Zepeda, E.A., M.E. Rothenberg, S. Weremowicz, M.N. Sarafi, C.C. Morton, and A.D. Luster. 1997. Genomic organization, complete sequence, and chromosomal location of the gene for human eotaxin (SCYA11), an eosinophilspecific CC chemokine. Genomics 41:471-476.
40. Bai, X., J.D. Chen, A.G. Yang, F. Torti, and S.Y. Chen. 1998. Genetic co-inactivation of macrophage-and Ttropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Gene Ther 5:984-994.
41. Dhanak, D., L.T. Christmann, M.G. Darcy, A.J. Jurewicz, R.M. Keenan, J. Lee, H.M. Sarau, K.L. Widdowson, and J.R. White. 2001. Discovery of potent and selective phenylalanine derived CCR3 antagonist. Part 1. Bioorg Med Chem Lett 11:1441-1444.
42. Varnes, J.G., D.S. Gardner, J.B. Santella, 3rd, J.V. Duncia, M. Estrella, P.S. Watson, C.M. Clark, S.S. Ko, P. Welch, M. Covington, N. Stowell, E. Wadman, P. Davies, K. Solomon, R.C. Newton, G.L. Trainor, C.P. Decicco, and D.A. Wacker. 2004. Discovery of Npropylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists. Bioorg Med Chem Lett 14:1645-1649.
43. Naya, A., K. Kobayashi, M. Ishikawa, K. Ohwaki, T. Saeki, K. Noguchi, and N. Ohtake. 2003. Structureactivity relationships of 2-(benzothiazolylthio) acetamide class of CCR3 selective antagonist. Chem Pharm Bull (Tokyo) 51:697-701.
44. Wakugawa, M., K. Nakamura, T. Kakinuma, and K. Tamaki. 2002. CC chemokine receptor 4 as a possible target for therapy of atopic dermatitis. Drug News Perspect 15:175-179.
45. Nakatani, T., Y. Kaburagi, Y. Shimada, M. Inaoki, K. Takehara, N. Mukaida, and S. Sato. 2001. CCR4 memory CD4{thorn} T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol 107:353-358.
46. Chvatchko, Y., A.J. Hoogewerf, A. Meyer, S. Alouani, P. Juillard, R. Buser, F. Conquet, A.E. Proudfoot, T.N. Wells, and C.A. Power. 2000. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 191:1755-1764.
47. Reiss, Y., A.E. Proudfoot, C.A. Power, J.J. Campbell, and E.C. Butcher. 2001. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 194:1541-1547.
48. Gonzalo, J.A., Y. Pan, C.M. Lloyd, G.Q. Jia, G. Yu, B. Dussault, C.A. Powers, A.E. Proudfoot, A.J. Coyle, D. Gearing, and J.C. Gutierrez-Ramos. 1999. Mouse monocytederived chemokine is involved in airway hyperreactivity and lung inflammation. J Immunol 163:403-411.
49. Alferink, J., I. Lieberam, W. Reindl, A. Behrens, S. Weiss, N. Huser, K. Gerauer, R. Ross, A.B. Reske-Kunz, P. Ahmad-Nejad, H. Wagner, and I. Forster. 2003. Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. J Exp Med 197:585-599.
50. Dragic, T., V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, K.A. Nagashima, C. Cayanan, P.J. Maddon, R.A. Koup, J.P. Moore, and W.A. Paxton. 1996. HIV-1 entry into CD4{thorn} cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
51. Adams, D.H., S. Hubscher, J. Fear, J. Johnston, S. Shaw, and S. Afford. 1996. Hepatic expression of macrophage inflammatory protein-1 alpha and macrophage inflammatory protein-1 beta after liver transplantation. Transplantation 61:817-825.
52. Doranz, B.J., J. Rucker, Y.J. Yi, R.J. Smyth, M. Samson, S.C. Peiper, M. Parmentier, R.G. Collman, and R.W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158.
53. Ditzel, H.J., M.M. Rosenkilde, P. Garred, M. Wang, K. Koefoed, C. Pedersen, D.R. Burton, and T.W. Schwartz. 1998. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc Natl Acad Sci U S A 95:5241-5245.
54. Ahmed, R.K., C. Nilsson, Y. Wang, T. Lehner, G. Biberfeld, and R. Thorstensson. 1999. Beta-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. J Gen Virol 80:1569-1574.
55. Fischereder, M., B. Luckow, B. Hocher, R.P. Wuthrich, U. Rothenpieler, H. Schneeberger, U. Panzer, R.A. Stahl, I.A. Hauser, K. Budde, H. Neumayer, B.K. Kramer, W. Land, and D. Schlondorff. 2001. CC chemokine receptor 5 and renaltransplant survival. Lancet 357:1758-1761.
56. Reyes, G. 2001. Development of CCR5 antagonists as a new class of anti-HIV therapeutic Abstract L11. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois. February 2001.
57. Shen, D.M., M. Shu, C.A. Willoughby, S. Shah, C.L. Lynch, J.J. Hale, S.G. Mills, K.T. Chapman, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, K. Lyons, J.V. Pivnichny, G.Y. Kwei, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M.D. Miller, and E.A. Emini. 2004. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds. Bioorg Med Chem Lett 14:941-945.
58. Shen, D.M., M. Shu, S.G. Mills, K.T. Chapman, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, G.Y. Kwei, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M.D. Miller, and E.A. Emini. 2004. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chain. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorg Med Chem Lett 14:935-939.
59. Ma, M., T. Wei, L. Boring, I.F. Charo, R.M. Ransohoff, and L.B. Jakeman. 2002. Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. J Neurosci Res 68:691-702.
60. Lynch, C.L., A.L. Gentry, J.J. Hale, S.G. Mills, M. MacCoss, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, M.A. Cascieri, G. Doss, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, and E.A. Emini. 2002. CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines. Bioorg Med Chem Lett 12:677-679.
61. Lynch, C.L., J.J. Hale, R.J. Budhu, A.L. Gentry, S.G. Mills, K.T. Chapman, M. MacCoss, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, M.A. Cascieri, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, and E.A. Emini. 2002. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV. Bioorg Med Chem Lett 12:3001-3004.
62. Lynch, C.L., J.J. Hale, R.J. Budhu, A.L. Gentry, P.E. Finke, C.G. Caldwell, S.G. Mills, M. MacCoss, D.M. Shen, K.T. Chapman, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, M.A. Cascieri, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, and E. Emini. 2003. CCR5 Antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity. Org Lett 5:2473-2475.
63. Lynch, C.L., C.A. Willoughby, J.J. Hale, E.J. Holson, R.J. Budhu, A.L. Gentry, K.G. Rosauer, C.G. Caldwell, P. Chen, S.G. Mills, M. MacCoss, S. Berk, L. Chen, K.T. Chapman, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, M.A. Cascieri, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, and E.A. Emini. 2003. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains. Bioorg Med Chem Lett 13:119-123.
64. Shankaran, K., K.L. Donnelly, S.K. Shah, R.N. Guthikonda, M. MacCoss, S.G. Mills, S.L. Gould, L. Malkowitz, S.J. Siciliano, M.S. Springer, A. Carella, G. Carver, D. Hazuda, K. Holmes, J. Kessler, J. Lineberger, M.D. Miller, E.A. Emini, and W.A. Schleif. 2004. Syntheses and SAR studies of 4-(heteroarylpiperidin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor. Bioorg Med Chem Lett 14:3419-3424.
65. Shankaran, K., K.L. Donnelly, S.K. Shah, C.G. Caldwell, P. Chen, P.E. Finke, B. Oates, M. MacCoss, S.G. Mills, J.A. DeMartino, S.L. Gould, L. Malkowitz, S.J. Siciliano, M.S. Springer, G. Kwei, A. Carella, G. Carver, R. Danzeisen, D. Hazuda, K. Holmes, J. Kessler, J. Lineberger, M.D. Miller, E.A. Emini, and W.A. Schleif. 2004. Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists. Bioorg Med Chem Lett 14:3589-3593.
66. Willoughby, C.A., S.C. Berk, K.G. Rosauer, S. Degrado, K.T. Chapman, S.L. Gould, M.S. Springer, L. Malkowitz, W.A. Schleif, D. Hazuda, M. Miller, J. Kessler, R. Danzeisen, K. Holmes, J. Lineberger, A. Carella, G. Carver, and E.A. Emini. 2001. Combinatorial synthesis of CCR5 antagonists. Bioorg Med Chem Lett 11:3137-3141.
67. Willoughby, C.A., K.G. Rosauer, J.J. Hale, R.J. Budhu, S.G. Mills, K.T. Chapman, M. MacCoss, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, S.J. Siciliano, M.A. Cascieri, A. Carella, G. Carver, K. Holmes, W.A. Schleif, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, and E.A. Emini. 2003. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains. Bioorg Med Chem Lett 13:427-431.
68. Finke, P.E., B. Oates, S.G. Mills, M. MacCoss, L. Malkowitz, M.S. Springer, S.L. Gould, J.A. DeMartino, A. Carella, G. Carver, K. Holmes, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, W.A. Schleif, and E.A. Emini. 2001. Antagonists of the human CCR5 receptor as anti-HIV-1 agent. Part 4: Synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg Med Chem Lett 11:2475-2479.
69. Finke, P.E., L.C. Meurer, B. Oates, S.G. Mills, M. MacCoss, L. Malkowitz, M.S. Springer, B.L. Daugherty, S.L. Gould, J.A. DeMartino, S.J. Siciliano, A. Carella, G. Carver, K. Holmes, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, W.A. Schleif, and E.A. Emini. 2001. Antagonists of the human CCR5 receptor as anti-HIV-1 agent. Part 2: Structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioorg Med Chem Lett 11:265-270.
70. Finke, P.E., L.C. Meurer, B. Oates, S.K. Shah, J.L. Loebach, S.G. Mills, M. MacCoss, L. Castonguay, L. Malkowitz, M.S. Springer, S.L. Gould, and J.A. DeMartino. 2001. Antagonists of the human CCR5 receptor as anti-HIV-1 agent. Part 3: A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes. Bioorg Med Chem Lett 11:2469-2473.
71. Hale, J.J., R.J. Budhu, S.G. Mills, M. MacCoss, L. Malkowitz, S. Siciliano, S.L. Gould, J.A. DeMartino, and M.S. Springer. 2001. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: Discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg Med Chem Lett 11:1437-1440.
72. Hale, J.J., R.J. Budhu, E.B. Holson, P.E. Finke, B. Oates, S.G. Mills, M. MacCoss, S.L. Gould, J.A. DeMartino, M.S. Springer, S. Siciliano, L. Malkowitz, W.A. Schleif, D. Hazuda, M. Miller, J. Kessler, R. Danzeisen, K. Holmes, J. Lineberger, A. Carella, G. Carver, and E. Emini. 2001. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. Bioorg Med Chem Lett 11:2741-2745.
73. Hale, J.J., R.J. Budhu, S.G. Mills, M. MacCoss, S.L. Gould, J.A. DeMartino, M.S. Springer, S.J. Siciliano, L. Malkowitz, W.A. Schleif, D. Hazuda, M. Miller, J. Kessler, R. Danzeisen, K. Holmes, J. Lineberger, A. Carella, G. Carver, and E.A. Emini. 2002. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: Polar functionality and its effect on anti-HIV-1 activity. Bioorg Med Chem Lett 12:2997-3000.
74. Dorn, C.P., P.E. Finke, B. Oates, R.J. Budhu, S.G. Mills, M. MacCoss, L. Malkowitz, M.S. Springer, B.L. Daugherty, S.L. Gould, J.A. DeMartino, S.J. Siciliano, A. Carella, G. Carver, K. Holmes, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, W.A. Schleif, and E.A. Emini. 2001. Antagonists of the human CCR5 receptor as anti-HIV-1 agent. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg Med Chem Lett 11:259-264.
75. Kim, D., L. Wang, C.G. Caldwell, P. Chen, P.E. Finke, B. Oates, M. MacCoss, S.G. Mills, L. Malkowitz, S.L. Gould, J.A. DeMartino, M.S. Springer, D. Hazuda, M. Miller, J. Kessler, R. Danzeisen, G. Carver, A. Carella, K. Holmes, J. Lineberger, W.A. Schleif, and E.A. Emini. 2001. Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. Bioorg Med Chem Lett 11:3099-3102.
76. Kim, D., L. Wang, C.G. Caldwell, P. Chen, P.E. Finke, B. Oates, M. MacCoss, S.G. Mills, L. Malkowitz, S.L. Gould, J.A. DeMartino, M.S. Springer, D. Hazuda, M. Miller, J. Kessler, R. Danzeisen, G. Carver, A. Carella, K. Holmes, J. Lineberger, W.A. Schleif, and E.A. Emini. 2001. Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. Bioorg Med Chem Lett 11:3103-3106.
77. Kumar, S., G.Y. Kwei, G.K. Poon, S.A. Iliff, Y. Wang, Q. Chen, R.B. Franklin, V. Didolkar, R.W. Wang, M. Yamazaki, S.H. Chiu, J.H. Lin, P.G. Pearson, and T.A. Baillie. 2003. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 304:1161-1171.
78. Castonguay, L.A., Y. Weng, W. Adolfsen, J. Di Salvo, R. Kilburn, C.G. Caldwell, B.L. Daugherty, P.E. Finke, J.J. Hale, C.L. Lynch, S.G. Mills, M. MacCoss, M.S. Springer, and J.A. DeMartino. 2003. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modelingguided mutagenesis study of the binding pocket. Biochemistry 42:1544-1550.
79. Arakaki, R., H. Tamamura, M. Premanathan, K. Kanbara, S. Ramanan, K. Mochizuki, M. Baba, N. Fujii, and H. Nakashima. 1999. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 73:1719-1723.
80. Bridger, G., R. Skerlj, A. Kaller, C. Harwig, D. Bogucki, T.R. Wilson, J. Crawford, E.J. McEacher, B. Atsma, S. Nan, Y. Zhou, D. Schols, C. Dennis, and R.M. Di Fluri. 2004. Chemokine receptor binding heterocyclic compounds. Patent number 6,734,191.
81. Guan, B., C. Minor, M. Dai, S. Ghosh, T.J. Jenkins, G. Li, D.F. Burdi, and R.A. Bennett. 2004. CCR8 inhibitors. Unites States Patent Application 20040209948.
82. Fleming, P., G.C.B. Harriman, Z. Shi, and S. Chen. 2003. CCR9 inhibitors and methods of use thereof. United States Patent Application 20040038976.
83. Ugashe, S., Z. Wei, J.J. Wright, A. Pennell, B. Premack, and T. Schall. 2004. Bis-aryl sulfonamides. United States Patent Application 20040167113.
84. Wu, C., C.E. Anderson, H. Bui, D. Gao, J. Kassir, W. Li, J. Wang, and R.V. Market. 2004. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists. United States Patent Application 20040180892.
85. Coughlan, C.M., C.M. McManus, M. Sharron, Z. Gao, D. Murphy, S. Jaffer, W. Choe, W. Chen, J. Hesselgesser, H. Gaylord, A. Kalyuzhny, V.M. Lee, B. Wolf, R.W. Doms, and D.L. Kolson. 2000. Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 97:591-600.
86. Hebert, C.A., R.V. Vitangcol, and J.B. Baker. 1991. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem 266:18989-18994.
87. Antony, V.B., J.W. Hott, S.L. Kunkel, S.W. Godbey, M.D. Burdick, and R.M. Strieter. 1995. Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am J Respir Cell Mol Biol 12:581-588.
88. White, J.R., J.M. Lee, P.R. Young, R.P. Hertzberg, A.J. Jurewicz, M.A. Chaikin, K. Widdowson, J.J. Foley, L.D. Martin, D.E. Griswold, and H.M. Sarau. 1998. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095-10098.
89. Widdowson, K.L., J.D. Elliott, D.F. Veber, H. Nie, M.C. Rutledge, B.W. McCleland, J.N. Xiang, A.J. Jurewicz, R.P. Hertzberg, J.J. Foley, D.E. Griswold, L. Martin, J.M. Lee, J.R. White, and H.M. Sarau. 2004. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem 47:1319-1321.
90. Baxter, A., C. Bennion, J. Bent, K. Boden, S. Brough, A. Cooper, E. Kinchin, N. Kindon, T. McInally, M. Mortimore, B. Roberts, and J. Unitt. 2003. Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. Bioorg Med Chem Lett 13:2625-2628.
91. Weidner-Wells, M.A., T.C. Henninger, S.A. Fraga-Spano, C.M. Boggs, M. Matheis, D.M. Ritchie, D.C. Argentieri, M.P. Wachter, and D.J. Hlasta. 2004. Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists. Bioorg Med Chem Lett 14:4307-4311.
92. Fischer, F.R., L. Santambrogio, Y. Luo, M.A. Berman, W.W. Hancock, and M.E. Dorf. 2000. Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. J Neuroimmunol 110:195-208.
93. Schall, T.J., D.J. Dairaghi, and B.E. McMAster. 2001. Compounds and methods for modulating CXCR3 function. World (PCT) Patent W0-161114.
94. Medina, J.C., M.G. Johnson, A.-R. Li, J. Liu, A.X. Huang, L.X. Zhu, and A.P. Marcus. 2002. CXCR3 Antagonists. United States Patent Application 20020169159.
95. Medina, J.C., M.G. Johnson, A.-R. Li, J. Liu, A.X. Huang, L.X. Zhu, and A.P. Marcus. 2003. CXCR3 Antagonists. United States Patent Application 20030069234.
96. Medina, J.C., M.G. Johnson, A.-R. Li, J. Liu, A.X. Huang, L.X. Zhu, and A.P. Marcus. 2003. CXCR3 Antagonists. United States Patent Application 20030055054.
97. Collins, T.L., M.G. Johnson, M.J., J.C. Medina, S. Miao, M. Schneider, and G.R. Tonn. 2004. CXCR3 Antagonists. United States Patent Application 2004075863.
98. Lin, C.-C., J.-F. Liu, C.-W. Chang, S.-J. Chen, Y. Xiang, and P.-C. Cheng. 2004. Aminoquinoline compounds. United States Patent Application 20040209902.
99. Aukrust, P., R.K. Berge, T. Ueland, E. Aaser, J.K. Damas, L. Wikeby, A. Brunsvig, F. Muller, K. Forfang, S.S. Froland, and L. Gullestad. 2001. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 37:485-491.
100. Murakami, K., H. Nomiyama, R. Miura, A. Follens, P. Fiten, E. Van Coillie, J. Van Damme, and G. Opdenakker. 1997. Structural and functional analysis of the promoter region of the human MCP-3 gene: transactivation of expression by novel recognition sequences adjacent to the transcription initiation site. DNA Cell Biol 16:173-183.
101. Doranz, B.J., J.F. Berson, J. Rucker, and R.W. Doms. 1997. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res 16:15-28.
102. Schols, D., J.A. Este, G. Henson, and E. De Clercq. 1997. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 35:147-156.
103. Hendrix, C.W., C. Flexner, R.T. MacFarland, C. Giandomenico, E.J. Fuchs, E. Redpath, G. Bridger, and G.W. Henson. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44:1667-1673.
104. Princen, K., S. Hatse, K. Vermeire, S. Aquaro, E. De Clercq, L.O. Gerlach, M. Rosenkilde, T.W. Schwartz, R. Skerlj, G. Bridger, and D. Schols. 2004. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J Virol 78:12996-13006.
105. Nagasawa, T., K. Tachibana, and T. Kishimoto. 1998. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 10:179-185.